Thakkar Karan, Spinardi Julia, Kyaw Moe H, Yang Jingyan, Mendoza Carlos Fernando, Ozbilgili Egemen, Taysi Bulent, Dodd Josie, Yarnoff Ben, Oh Helen M
Asia Medical Affairs, Pfizer Inc, New York, NY, USA.
Medical and Scientific Affairs, Pfizer Inc, New York, NY, USA.
Expert Rev Vaccines. 2024 Jan-Dec;23(1):16-26. doi: 10.1080/14760584.2023.2290931. Epub 2023 Dec 12.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 has been a dynamically changing virus, requiring the development of adapted vaccines. This study estimated the potential public health impact alternative vaccination strategies for COVID-19 in Singapore.
The outcomes of alternative vaccination strategies with a future adapted vaccine were estimated using a combined Markov decision tree model. The population was stratified by high- and standard-risk. Using age-specific inputs informed by local surveillance data and published sources, the model estimated health (case numbers, hospitalizations, and deaths) and economic (medical costs and productivity losses) outcomes in different age and risk subpopulations.
Booster vaccination in only the elderly and high-risk subpopulation was estimated to avert 278,614 cases 21,558 hospitalizations, 239 deaths, Singapore dollars (SGD) 277 million in direct medical costs, and SGD 684 million in indirect medical costs. These benefits increased as vaccination was expanded to other subpopulations. Increasing the booster vaccination coverage to 75% of the standard-risk population averted more deaths (3%), hospitalizations (29%), infections (145%), direct costs (90%), and indirect costs (192%) compared to the base case.
Broader vaccination strategies using an adapted booster vaccine could have substantial public health and economic impact in Singapore.
导致 COVID-19 的严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)是一种动态变化的病毒,需要研发适应性疫苗。本研究评估了新加坡针对 COVID-19 的替代疫苗接种策略对公共卫生的潜在影响。
使用马尔可夫决策树联合模型评估未来适应性疫苗的替代疫苗接种策略的效果。人群按高风险和标准风险分层。利用当地监测数据和已发表资料中的特定年龄输入数据,该模型估计了不同年龄和风险亚人群中的健康(病例数、住院人数和死亡人数)和经济(医疗费用和生产力损失)结果。
仅对老年人和高风险亚人群进行加强疫苗接种估计可避免 278,614 例病例、21,558 次住院、239 例死亡,节省 2.77 亿新加坡元的直接医疗费用和 6.84 亿新加坡元 的间接医疗费用。随着疫苗接种扩大到其他亚人群,这些益处会增加。与基线情况相比,将加强疫苗接种覆盖率提高到标准风险人群的 75%可避免更多死亡(3%)、住院(29%)、感染(145%)、直接费用(90%)和间接费用(192%)。
在新加坡,使用适应性加强疫苗的更广泛疫苗接种策略可能会对公共卫生和经济产生重大影响。